Hyphens Pharma grants Swiss pharma company rights to commercialise Cerapro MED Skin Barrier Cream

Nicole LimMon, Jan 05, 2026 • 06:03 PM GMT+08 • 1 min read

Hyphens Pharma grants Swiss pharma company rights to commercialise Cerapro MED Skin Barrier Cream

The out-licensing agreement will result in Hyphens Pharma receiving an upfront fee and customary royalties on sales. Photo: Albert Chua/The Edge Singapore

Hyphens Pharma International has granted the rights to commercialise its product Cerapro MED Skin Barrier Cream to Louis Widmer covering six European countries.

This is done via a licensing, supply and commercialisation agreement which spans Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands.

The out-licensing agreement will result in Hyphens Pharma receiving an upfront fee and customary royalties on sales.

Cerapro is a patented formula which lowers skin pH and helps restore skin barrier. It targets atopic dermatitis, a common form of eczema.

CEO of Louis Widmer, Annemarie Widmer, says that Cerapro will be the new flagship product of the company's Remederm line, which is a leader in Europe in both specialist retailers and doctors for the care of dry, very dry and atopic skin.

Shares in Hyphens Pharma closed 1 cent higher or 2.985% up at 34.5 cents on Jan 5.